Law  firm  Taylor  Wessing  Prague  provided  comprehensive  legal  advice  to  the  German  Biotest  group,  a specialist  in   innovative  haematology,  clinical  immunology  and  intensive  care  medicine,   and  to  its subsidiary  Plasma  Service  Europe  with  respect to  its  acquisition  of  Czech  company  Cara  Plasma  s.r.o.,
which operates plasma centers in the Czech Republic.

Taylor  Wessing's  complex  legal  services  included  among  others  a  due  diligence  in  Cara  Plasma,  drafting  and negotiating  the  contractual  documentation  including  a  call  option  and  loan  and  security  arrangements  as  well  as closing assistance.

Cara Plasma operates Prague s most modern plasma center, which is also one of the European top 10.  "We are pleased  to  assist  in  such  a  prestigious  transaction  where  both  parties  are  market  leaders  with  high  reputations" commented Thilo Hoffmann, the Taylor Wessing Prague Partner, who led the project team, adding that, "due to the extensive  industry-specific  knowledge  and  focus  on  the  life  science  sector  of  our  law  firm  we  were  able  to understand the intentions of our client and therefore assist him in the best possible way."

Hoffmann has extensive experience in all areas of Corporate and M&A. Denisa Rajdova also worked on the project.    

Taylor Wessing Prague provided the aforementioned comprehensive legal services between March and July 2017. The parties agreed to keep the terms and conditions of the transaction confidential.

About Biotest:
Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. The value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest also develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest currently employs more than 2,500 people worldwide.

About Cara Plasma s.r.o.:
Company Cara Plasma s.r.o. was founded in 2013 as a Czech family company and established a state-of-the-art blood collection center in Prague which is one of Europe's top 10. The center was opened in September 2013.